Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial

Autor: Lowenberg, B., Pabst, T., Maertens, J., Gradowska, P., Biemond, B.J., Spertini, O., Vellenga, E., Griskevicius, L., Tick, L.W., Jongen-Lavrencic, M., Kooy, M.V., Vekemans, M.C., Velden, W.J.F.M. van der, Beverloo, B., Michaux, L., Graux, C., Deeren, D., Weerdt, O. de, Esser, J.W.J. van, Bargetzi, M., Klein, S.K., Gadisseur, A., Westerweel, P.E., Veelken, H., Gregor, M., Silzle, T., Lammeren-Venema, D. van, Moors, I., Breems, D.A., Hoogendoorn, M., Legdeur, M.C.J.C., Fischer, T., Kuball, J., Cornelissen, J., Porkka, K., Juliusson, G., Meyer, P., Hoglund, M., Gjertsen, B.T., Janssen, J.J.W.M., Huls, G., Passweg, J., Cloos, J., Valk, P.J.M., Elssen, C.H.M.J. van, Manz, M.G., Floisand, Y., Ossenkoppele, G.J., Dutch-Belgian Hemato-Oncology Coop, Swiss Grp Clinical Canc Res SAKK

Publikováno v: Blood Adv
Blood advances, 5(4), 1110-1121. American Society of Hematology
Blood advances
Blood, 5(4), 1110-1121. American Society of Hematology
Löwenberg, B, Pabst, T, Maertens, J, Gradowska, P, Biemond, B J, Spertini, O, Vellenga, E, Griskevicius, L, Tick, L W, Jongen-Lavrencic, M, Kooy, M V M, Vekemans, M-C, van der Velden, W J F M, Beverloo, B, Michaux, L, Graux, C, Deeren, D, Weerdt, O D, Esser, J W J V, Klein, M B S K, Gadisseur, A, Westerweel, P E, Veelken, H, Gregor, M, Silzle, T, Lammeren-Venema, D Ë V, Moors, I, Breems, D A, Hoogendoorn, M, Legdeur, M-C J C, Fischer, T, Kuball, J, Porkka, J C K, Juliusson, G, Meyer, P, Höglund, M, Gjertsen, B T, Janssen, J J W M, Huls, G, Passweg, J, Cloos, J, Valk, P J M, Elssen, C H M J V, Manz, M G, Floisand, Y & Ossenkoppele, G J 2021, ' Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: The HOVON-SAKK-132 trial ', Blood, vol. 5, no. 4, pp. 1110-1121 . https://doi.org/10.1182/bloodadvances.2020003855
BLOOD ADVANCES
Blood Advances, 5(4), 1110-1121. AMER SOC HEMATOLOGY
Blood Advances, 5, 1110-1121
Blood advances, 5(4), 1110-1121. The American Society of Hematology
Blood advances, Vol. 5, no. 4, p. 1110-1121 (2021)
Blood Advances, 5, 4, pp. 1110-1121
Blood, 5(4), 1110-1121. AMER SOC HEMATOLOGY
Blood advances, Washington : American Society of Hematology, 2021, vol. 5, no. 4, p. 1110-1121

Lenalidomide, an antineoplastic and immunomodulatory drug, has therapeutic activity in acute myeloid leukemia (AML), but definitive studies about its therapeutic utility have been lacking. In a phase 3 study, we compared 2 induction regimens in newly

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67b667f8652f65ff1c599befd9584961
https://pubmed.ncbi.nlm.nih.gov/33616652

An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens

Autor: Sobas M, Montesinos P, Boluda B, Bernal T, Vellenga E, Nomdedeu J, Gonzalez-Campos J, Chillon M, Holowiecka A, Esteve J, Bergua J, Gonzalez-Sanmiguel J, Gil-Cortes C, Tormo M, Salamero O, Manso F, Fernandez I, de la Serna J, Moreno M, Perez-Encinas M, Krsnik I, Ribera J, Escoda L, Lowenberg B, Sanz M, de Heredia J, Hernandez J, Arias J, Ramos F, Roman A, Negri S, Rayon C, Fernandez-Calvo F, Diaz-Mediavilla J, Gil C, Olave M, Amutio E, Pedro C, Gorosquieta A, Viguria M, Zudaire M, Molero T, Sayas M, Guardia R, Esquembre C, Garcia R, Alcala A, Lopez J, Rubio V, Amigo M, Linares M, San Miguel J, Coruna A, Deben G, de la Camara R, Molines A, Loureiro C, Allegue M, Amador L, Marti J, Madero L, Lassaletta A, Cabezudo M, Garcia-Larana J, Rojas R, Ortega F, Penarrubia M, Puente F, Lopez-Ibor B, Brunet S, Ibanez J, Sanchez P, Novo A, Guinea J, Montero A, Gonzalez M, Martin G, Martinez J, Verdeguer A, Garcia P, Conde E, Garcia J, Capote F, Bueno J, Bastida P, Rubio A, Fuster J, Gonzalez J, Perez I, Molina J, Mateos M, Ardaiz M, Rodriguez-calvillo M, Poderos C, Arnan M, Duarte R, Diaz-Morfa M, Martin-Chacon E, Calvo-Villas J, Garcia-Belmonte D, Hernandez-Maraver D, Ossenkoppele G, van der Lelie J, Sonneveld P, Zijlmans M, Maertens J, de Valk B, Wijermans P, de Groot M, Schouten H, Biesma D, van Marwijk M, de Lisa E, Golos A, Ejduk A, Armatys A, Zarzycka E, Knopinska W, Miskiewicz W, Jastrzab B, Pluta A, Paluszewska M, Podhorecka M, Gromek T, Jakubas B, Majcherek M, Skret A, Watek M, Charlinski G, Calbecka M, Becht R, Gadomska A, Rzenno E, Piszcz J, Grosicki S, Palmer L, Ciarlo S, Bezares F, Rojas F, Longoni H, Gelemur M, Fazio P, Canepa C, Saba S, Balladares G, Negri P, Giunta M, Milone J, Lafalse D, Sossa C, Jaramillo F, Mayer J, Protivankova M, Scwarz J, PETHEMA Cooperative Grp, HOVON Cooperative Grp, PALG Cooperative Grp, GATLA Cooperative Grp

Publikováno v: LEUKEMIA & LYMPHOMA
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname

Out of 956, there were 95 (10%) CD56+ APL patients treated with PETHEMA ATRA and chemotherapy. CD56+ expression was associated with high WBC, BCR3 isoform, and co-expression of CD2, CD34, CD7, HLA-DR, CD15, and CD117 antigens. CD56+ vs CD56- APL pres

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::2899368e79ad54c038cc13c56e7f32b6
https://fundanet.isabial.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=8035

Richtlijn Acute promyelocytenleukemie (APL): richtlijnen voor diagnostiek en behandeling

Autor: Huls, Geert, Lowenberg, B., van de Loosdrecht, A.A., Janssen, J.J.W.M., Jongen-Lavrencic, M., Raaijmakers, M., Wouters, B., Von dem Borne, Peter A., Kuball, Jurgen, Biemond, Bart J., Van Gelder, Michel, van der Velden, W.J.F.M, de Weerdt, Okke, van Marwijk Kooy, Rien, Klein, Saskia, van der Poel, M., van Rhenen, A., Jong, J.J.M. de, Valk, P, van der Reijden, B., Cornelissen, J.J., Vellenga, Edo, Ossenkoppele, G.

Publikováno v: Nederlands Tijdschrift voor Hematologie, 15(8), 396-401

Acute myeloïde leukemie (AML) is een heterogene ziekte die wordt gekenmerkt door (oligo)klonale maligne hematopoëse met een blokkade in de differentiatie en daardoor een excessieve toename van leukemische blasten. Acute promyelocytenleukemie (APL)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::70d70c04915b31d7d87cd5cd86424598
https://research.rug.nl/en/publications/a1dc0a8a-cd49-4f78-ad1b-5c273a73026c

Molecular Minimal Residual Disease in Acute Myeloid Leukemia REPLY

Autor: Lowenberg, B, Valk, Peter

Publikováno v: New England Journal of Medicine, 378(25), 2443-2443. Massachussetts Medical Society

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::a7807c01946f3365b2fafbda38e36089
https://pure.eur.nl/en/publications/110762e0-65e9-4d33-bf2d-95c98ab62418

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years

Autor: Cornelissen, J.J., Versluis, J., Passweg, J.R., Putten, W.L. van, Manz, M.G., Maertens, J., Beverloo, H.B., Valk, P.J., Kooy, M., Wijermans, P.W., Schaafsma, M.R., Biemond, B.J., Vekemans, M.C., Breems, D.A., Verdonck, L.F., Fey, M.F., Jongen-Lavrencic, M., Janssen, J.J.W.M., Huls, G.A., Kuball, J., Pabst, T., Graux, C., Schouten, H.C., Gratwohl, A., Vellenga, E., Ossenkoppele, G., Lowenberg, B.

Publikováno v: Leukemia, 29(5), 1041-1050. Nature Publishing Group
Leukemia
Cornelissen, J J, Versluis, J, Passweg, J R, van Putten, W L J, Manz, M G, Maertens, J, Bverloo, H B, Valk, P J M, Kooy, M V, Wijermans, P W, Schaafsma, M R, Biemond, B J, Vekemans, M C, Breems, D A, Verdonck, L F, Fey, M F, Jongen-Lavrencic, M, Janssen, J J W M, Huls, G, Kuball, J, Pabst, T, Graux, C, Schouten, H C, Gratwohl, A, Vellenga, E, Ossenkoppele, G & Lowenberg, B 2015, ' Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years ', Leukemia, vol. 29, no. 5, pp. 1041-1050 . https://doi.org/10.1038/leu.2014.332
Leukemia, 29, 5, pp. 1041-50
Leukemia, 29, 1041-50
Leukemia, 29(5), 1041. Nature Publishing Group

The preferred type of post-remission therapy (PRT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1) is a subject of continued debate, especially in patients at higher risk of nonrelapse mortality (NRM), including patien

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f83e7835df002e6230923c1eedd6b367
https://hdl.handle.net/2066/154835